TG Therapeutics, Inc. (TGTX) saw its stock climb on Wednesday after presenting updated data from its Phase 3 trials for BRIUMVI (ublituximab-xiiy), a potential treatment for relapsing forms of multiple sclerosis. The data, shared at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, showed sustained clinical benefits with continued use of BRIUMVI, including reduced relapse rates and a low rate of disability progression.